English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In the United States alone, new prostate cancer cases for 2016 were estimated at 180,890 and deaths at 26,120. Focal therapies for low risk and intermediate risk localized prostate cancer are increasingly being explored. Additionally, new treatments for patients in a salvage setting are being studied. Our objective is to investigate the efficacy of using MR-guided laser focal therapy for MR visible prostate cancer utilizing a transrectal approach for laser applicator placement and therapy delivery in an outpatient setting. Lasers have been used for soft tissue necrotization for decades. A commercially available MR-guided biopsy system accommodates insertion of a 980nm laser fiber for insertion into biopsy proven cancerous lesions facilitating ablation of MR-visible tumor.

MP30-02 TRANSRECTALLY DELIVERED, OUTPATIENT MRI-GUIDED LASER FOCAL THERAPY OF PROSTATE CANCER: SEVEN YEAR INTERIM RESULTS OF NCT #02243033